Konvent Der Barmherzigen Brueder
- Address
- Seilerstaette 2, 4020 Linz, Austria
Cardiovascular and Metabolic Research
At Konvent Der Barmherzigen Brueder in Linz, a major part of the clinical research portfolio focuses on cardiovascular diseases and metabolic disorders, including atherosclerotic cardiovascular disease, hypertension, type 2 diabetes, obesity, and severe hypertriglyceridemia. These studies are designed to test new ways to reduce heart-related events, improve risk-factor control, and support better long-term prevention.
- Testing therapies aimed at lowering major cardiovascular event risk
- Studying treatments for elevated lipoprotein(a) and familial cholesterol disorders
- Evaluating approaches to improve outcomes in diabetes, obesity, and kidney-related cardiovascular risk
This area reflects a strong interest in prevention and treatment strategies that may help reduce serious complications in people with high cardiometabolic risk.
Neurology and Stroke Care
The site’s Neurology department is active in trials for multiple sclerosis, migraine, stroke, and spasticity. Research in this field is centered on improving symptom control, preventing recurrent events, and assessing the safety and effectiveness of new or established treatments for neurological conditions.
- Evaluating medicines for migraine prevention and symptom relief
- Studying stroke prevention after ischemic stroke or transient ischemic attack
- Assessing longer-term treatment options for multiple sclerosis and post-stroke spasticity
These trials show a broad commitment to both chronic neurological disease management and recovery-focused care.
Ophthalmology and Vision Disorders
Clinical trials at the site also address eye diseases, especially age-related macular degeneration, macular edema, and myopia. The research aims to slow vision loss, improve visual function, and explore new treatment options for common retinal and refractive conditions.
- Investigating therapies for retinal swelling and degenerative retinal disease
- Testing approaches to slow myopia progression in children
- Assessing safety and vision outcomes of emerging eye treatments
This field is especially relevant for patients seeking better control of progressive vision problems and for clinicians looking for improved eye care options.
Oncology and Hematology
The research portfolio includes studies in neoplasms and hematologic diseases, with trials involving multiple myeloma, colorectal cancer, gastric and gastroesophageal junction cancer, pancreatic cancer, ovarian cancer, and HPV-associated cancers. These trials are focused on improving survival, extending disease control, and refining treatment strategies for both solid tumors and blood cancers.
- Testing new combinations for multiple myeloma and infection prevention during treatment
- Evaluating treatment effectiveness in advanced gastrointestinal and gynecologic cancers
- Studying targeted and immune-based approaches for cancer care
The site contributes to oncology research that seeks better outcomes for patients with difficult-to-treat or recurrent cancers.
Digestive, Immune, and Other Specialty Areas
Beyond its core neurology focus, the site supports trials in digestive system diseases, immune system diseases, musculoskeletal disorders, urogenital conditions, and virus diseases. Areas of interest include ulcerative colitis, radiation proctitis, and immune-related infection prevention, alongside studies in metabolic health and inflammatory conditions.
- Improving bowel symptoms and quality of life in ulcerative colitis and proctitis
- Evaluating infection prevention in people with weakened immune function
- Exploring treatment support for metabolic and inflammatory complications across several disease areas
This diverse activity highlights a broad clinical research environment with links between internal medicine, immune care, and symptom management.
Site Overview
Activity Indicator
Last 6 months
Trial Flow
How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.
Top 4 of 9 therapeutic areas and 15 of 66 IMPs, ranked by number of trials.
Compounds & Molecules Timeline
The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.
Top 40 of 49 compounds, ranked by number of trials.
Sponsor & Partnership
Top sponsors by active trials, and the ones that have come back for more than one study.
Sponsor Network
Top 8 by active trials.
- 1Amgen Inc.2active
lock +7 more on a paid plan
Partnership History
Sponsors with repeated collaboration (≥ 2 trials).
- 1Novartis Pharma AG4trials
lock +5 more on a paid plan
Sponsor Network Graph
How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.
Country Benchmark
Compared to 152 other sites in Austria
Therapeutic Area Benchmark — Austria
Select a therapeutic area to compare against other sites in Austria.
Competitor Comparison
Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.
Country: Austria
Market Share
Country: Austria
Therapeutic Area Market Share
Select a therapeutic area to view its disease coverage breakdown.
Heat Maps & Advanced Analytics
How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.
Other Trials in Konvent Der Barmherzigen Brueder
lock Showing 1 of 31 trials — the rest is available on a paid plan.
| Trial | Sponsor | Phase | Status | Start Date | End Date |
|---|---|---|---|---|---|
| (22153) Randomized, Double-Masked, Active-Controlled, Phase 3 Study of the Efficacy and Safety of Aflibercept 8 mg in Macular Edema Secondary to Retinal Vein Occlusion | Bayer AG | Phase III | Not Recruiting | Sep 2023 | May 2025 |
IMP list
lock Showing 1 of 66 compounds — the rest is available on a paid plan.
| IMP | Trials | Status | First start | Last start |
|---|---|---|---|---|
| Dapagliflozin | 2 | Unknown | 2023-08-02 | 2024-07-30 |
Request feasibility information
Ask this centre about capacity, equipment and patient population.
Upgrade this site to Business Plan
Own the profile, publish your feasibility data and reach sponsors directly.
Is something out of date?
Tell us what needs correcting and we'll update this profile.
lock Available to Business plan sites only.
